Open AccessImmunobridging efficacy of a tetravalent dengue vaccine against dengue and against hospitalized dengue from children/adolescents to adults in highly endemic countries
Author(s) -
Ying Huang,
Zoe Moodie,
Michal Juraska,
Youyi Fong,
Lindsay N. Carpp,
Laurent Chambonneau,
Diana Coronel,
Gustavo H. Dayan,
Carlos A. DiazGranados,
Peter B. Gilbert
Publication year - 2020
Publication title -
transactions of the royal society of tropical medicine and hygiene
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.725
H-Index - 105
eISSN - 1878-3503
pISSN - 0035-9203
DOI - 10.1093/trstmh/traa154
Subject(s) - dengue fever , dengue vaccine , titer , dengue virus , medicine , serotype , virology , pediatrics , virus
The recombinant tetravalent live-attenuated dengue vaccine based on the YF 17D vaccine virus backbone (CYD-TDV) demonstrated vaccine efficacy (VE) against symptomatic, virologically confirmed dengue of any serotype from month 13 to month 25 (VCD-DENV-AnyM13→M25) in the CYD14 (2-14-y-olds) and CYD15 (9-16-y-olds) phase 3 trials. Fifty percent plaque reduction neutralization test (PRNT50) titers are a potential surrogate for immunobridging VE to adults.